41Ca and accelerator mass spectrometry to monitor calcium metabolism in end stage renal disease patients

Clinical Chemistry

Volumn 51, Issue 11, 2005, Pages 2095-2102

  Fitzgerald, Robert L ^a,b,f   Hillegonds, Darren J ^d   Burton, Douglas W ^a   Griffin, Terrance L ^a   Mullaney, Scott ^a,c   Vogel, John S ^d,e   Deftos, Leonard J ^a,c   Herold, David A ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CALCIUM; CALCIUM 41; ENDOTOXIN; ISOTOPE; UNCLASSIFIED DRUG;

ACCELERATOR MASS SPECTROMETRY; ACCURACY; ANALYTIC METHOD; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CATION EXCHANGE; CLINICAL ARTICLE; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY FAILURE; MASS SPECTROMETRY; MONITORING; OSTEOLYSIS; PRECIPITATION; QUANTITATIVE ANALYSIS; BLOOD; BONE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; METABOLISM; METHODOLOGY;

BONE AND BONES; CALCIUM; CALCIUM RADIOISOTOPES; HUMANS; KIDNEY FAILURE, CHRONIC; MASS SPECTROMETRY;

EID: 27444435999     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.049650     Document Type: Article

References (43)

1. 48Ca in the clinical measurement of intestinal calcium absorption. Calcif Tissue Res 1978;10:5-11.
2. deGrazia JA, Ivanovick P, Fellows H, Rich C. A double isotope method of measurement of intestinal absorption of calcium in man. J Lab Clin Med 1965;66:822-9.
3. 44Ca) in evaluation of calcium absorption in Beijing adolescents with low vitamin D status. Food Nutr Bull 2002;23:42-7.
4. Vogel JS, Turteltaub KW, Finkel R, Nelson DE. Accelerator mass spectrometry. Anal Chem 1995;67:353A-9A.
5. Freeman SPHT, Vogel JS. Biomedical accelerator mass spectrometry. Int J Mass Spectrom Ion Process 1995;143:247-56.
6. Vogel JS, Turteltaub KW. Accelerator mass spectrometry in biomedical research. Nucl Instrum Methods Phys Res B 1994;92:445-53.
7. Lu CM, Burton DW, Fitzgerald RL, Deftos U, Buchholz BA, Vogel JS, et al. Mass spectrometric immunoassay for parathyroid hormone-related protein. Anal Chem 2002;74:5507-12.
8. Turteltaub KW, Felton JS, Gledhill BL, Vogel JS, Southon JR, Caffee MW, et al. Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci USA 1990;87:5288-92.
9. Buchholz BA, Fultz E, Haack KW, Vogel JS, Gilman SD, Gee SJ, et al. HPLC-accelerator MS measurement of atrazine metabolites in human urine after dermal exposure. Anal Chem 1999;71:3519-25.
10. 41Ca by accelerator mass spectrometry to quantitate small changes in individual human bone turnover rates. J Assoc Lab Autom 2004;9:99-102.
11. 41Ca. Z Phys A Hadrons Nuclei 1991;340:249-54.
12. 41Ca tracer. Nucl Instrum Methods Phys Res B 1997;123:266-70.
13. 45Ca. Nucl Instrum Methods Phys Res B 2000;172:930-3.
14. 45Ca. Appl Radiat Isot 2000;52:407-13.
15. Demers LM. Biochemical markers in the management of patients with metastatic bone disease. Clin Chem 1999;45:1131-2.
16. Kamel S, Fardellone P, Meddah B, Lorget-Gondelmann F, Sebert JL, Brazier M. Response of several markers of bone collagen degradation to calcium supplementation in postmenopausal women with low calcium intake. Clin Chem 1998;44:1437-42.
17. Kleerekoper M. Biochemical markers of bone turnover: why theory, research, and clinical practice are still in conflict. Clin Chem 2001;47:1347-9.
18. Chailurkit L, Ongphiphadhanakul B, Piaseu N, Saetung S, Rajatanavin R. Biochemical markers of bone turnover and response to bone mineral density to intervention in early postmenopausal women: an experience in a clinical laboratory. Clin Chem 2001;47:1038-88.
19. Vesper HW, Demers LM, Eastell R, Garnero P, Kleerekoper M, Robins SP, et al. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chem 2002;48:220-35.
20. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem 1999;45:1359-68.
21. Trueba D, Sawaya BP, Mawad H, Malluche HH. Bone biopsy: indications, techniques and complications. Semin Dial 2003;16:341-5.
22. 41Ca AMS standards. Nucl Instrum Methods Phys Research B 2000;172:399-403.
23. US Pharmacopeia. United States pharmacopeial convention USP 25. NF 20, the national formulary. 85. Bacterial endotoxin test. Rockville, MD: US Pharmacopeia, 2002:1889-93.
24. US Pharmacopeia. United States pharmacopeial convention USP 25. NF 20, the national formulary. 71. Sterility tests. Rockville, MD: US Pharmacopeia, 2002:1878-83.
25. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 2002;17:2094-105.
26. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;(Suppl 42):1-201.
27. Deftos, U. Radioimmunoassay for parathyroid hormone. In: Jaffee W, Behrman H, eds. Methods in hormone radioimmunoassay. New York: Academic Press, 1974:231-47.
28. McGonigle RJ, Wallin JD, Husserl F, Deftos U, Rice JC, O'Neill WJ Jr, et al. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure. J Lab Clin Med 1984;104:1016-26.
29. 41Ca isotopes in urine, serum, and saliva samples. Anal Biochem 2004;332:193-5.
30. 41Ca AMS measurements at LLNL. Nucl Instrum Methods Phys Res B 1995;99:557-61.
31. CRC. Table of the isotopes. In: CRC handbook of chemistry and physics, 81st ed. Boca Raton, FL: CRC Press, 2000:11-51.
32. 41Ca tracing. Nucl Instrum Methods Phys Res B 1994;92:483-8.
33. Cember H. Introduction to health physics, 3rd ed. New York: McGraw-Hill, 1996:169-223.
34. National Council on Radiation Protection and Measurements (NCRP). Report no. 94. Exposure of the population of the United States and Canada from natural background radiation. Bethesda, MD: NCRP, 1987:22.
35. Cochran M, Cochran M, Neville A, Marshall EA. Comparison of bone formation rates measured by radiocalcium kinetics and double-tetracycline labeling in maintenance dialysis patients. Calcif Tissue Int 1994;54:392-8.
36. 12 by diode-laser-based RIMS. Fresenius J Anal Chem 2001;370:508-12.
37. 41Ca atoms with a magneto-optical trap. Phys Rev Lett 2004;92:153002.
38. Harrison HE, Harrison HC. Studies with radiocalcium: The intestinal absorption of calcium. J Biol Chem 1951;188:83-90.
39. 41Ca distribution in mice [Abstract]. J Bone Miner Res 2004;19:S239.
40. Bronner F, Harris RS, Maletskos CJ, Benda CE. Studies in calcium metabolism. The fate of intravenously injected radiocalcium in human beings. J Clin Invest 1956;35:78-88.
41. Parfitt AM. Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone 2003;33:259-63.
42. Santini SA, Carrozza C, Vulpio C, Capoluongo E, Luciani G, Lulli P, et al. Assessment of parathyroid function in clinical practice: which parathyroid hormone assay is better. Clin Chem 2004;50:1247-50.
43. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.